| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small sample | 100.0% (4/4) | 50.0% (2/4) | +0.1% | +0.8% | -1.7% |
| 20D | 4Small sample | 100.0% (4/4) | 75.0% (3/4) | +3.2% | +1.5% | -5.9% |
| 60D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -7.0% | -7.1% | -22.4% |
| 120D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | -11.0% | -11.0% | -24.2% |
COMPANY RESEARCH
AstraZeneca PLC
AZN.L · Sweden · Healthcare · Drug Manufacturers—General
INSIDER SIGNAL
Insider activity score：65.8 / 100
3 insiders · 5 purchase events · €8.96m net purchases
Europe #154 · Sweden #32
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
Cluster+29.8 / 35
How many distinct insiders bought in the cluster
Purchase size+25.0 / 25
Purchase value relative to company size and liquidity
Role+20.0 / 20
The seniority and relevance of participating insiders
Recency+1.0 / 10
How recently the purchases occurred
Conviction+10.0 / 10
How clearly buying stands out from other activity
What is holding the score back?
- ⚠ Purchase activity is becoming less recent
- ✓ Broad buyer cluster · 4+ distinct filers
- ✓ Strong insider role · ceo/chair involved
The role contribution uses the inverted role input of the current European model.
Buying concentration
96%
Largest buyer：Pascal Soriot · 7.26m GBP
Gross qualified purchase transaction-line value：7.56m GBP
The headline € total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.
This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| Pascal Soriot | 121.02 GBP | Sep 14, 2026 |
| Michel Demare | 121.213296 GBP | Sep 14, 2026 |
| Aradhana Sarin | 0 GBP | Sep 14, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 3 distinct reported filers
- Peak time window
- 2026-09-14 to 2026-09-14
- Current breadth input
- 0.850 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Recent eligible purchase
Pascal Soriot · 7.26m GBP · Price 121.02 GBP · Sep 14, 2026 - 🟢 Eligible purchase
Michel Demare · 303k GBP · Price 121.213296 GBP · Sep 14, 2026 - 🟢 Large eligible purchase
Aradhana Sarin · 0 GBP · Price 0 GBP · Sep 14, 2026 - 🟡 2 remaining qualified transaction line(s) across 2 disclosure(s)
Insider vs stock price
3 purchase day(s), 5 purchase line(s) in the 180-day window.
Daily close (GBp)Day with an insider purchaseTwo or more insiders the same day
Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.
If you had followed the purchase
Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.
| Made public | Insiders | In this stock, now | In the median peer stock, now | Difference |
|---|---|---|---|---|
| 2026-05-18 | 1 | 926 −7.4% | 1,056 +5.6% | −130 −13.0 pts |
| 2026-08-19 | 1 | 1,054 +5.4% | 987 −1.3% | +67 +6.7 pts |
| 2026-09-15 | 2 | 1,048 +4.8% | 1,015 +1.5% | +33 +3.3 pts |
| 2026-09-17 | 1 | 1,022 +2.2% | 1,000 +0.0% | +22 +2.2 pts |
3 of 4 disclosure day(s) ended ahead of the median peer stock.
Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (113 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.
Insider timeline
3 insiders bought on the same day, 14 Sep: 2 CEO / chair, 1 CFO. The share closed at 12,154.00 that day and at 12,698.00 most recently (+4.5%). That week 173 companies across Europe disclosed insider purchases, an ordinary week (18 of the last 26).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount. A filing that states no amount gets the smallest dot.
▮Purple band: several insiders bought within 15 days
The band marks the stretch with the most different buyers: at most 15 days long and at least two people. Here it is 14 Sep, with 3 insiders. Only the strongest stretch is marked. Several people deciding the same thing is harder to explain by one person's private reasons, but insiders often buy together just after a closed period ends, so compare it with the grey weekly bars.
Blue line: this share's price, −12.8% over these six months
The closing price of each day, from 14,560.00 on 2026-04-21 to 12,698.00 on 2026-10-15. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, +2.6%
Taken from the 491 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −12.8%, the typical one +2.6%, 15.4 points behind. It is not an index and not a comparison within one industry.
▂Grey bars: companies across Europe disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases. The purple bar is the week of the band above: 173 companies, number 18 of the last 26 weeks. If that week was a peak anyway, buying together is less special than it looks.
This company: insiders buying per month, last 12 months
Nov
Dec
Jan
Feb
2Mar
Apr
1May
Jun
Jul
1Aug
3Sep
Oct
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since | Earlier purchases |
|---|---|---|---|---|---|---|---|
| Pascal Soriot | CEO / chair | 2 | — | 7.3M GBP | 2026-05-14 | −7.6% | fewer than 5 completed |
| Aradhana Sarin | CFO | 2 | — | — | 2026-08-17 | +9.8% | fewer than 5 completed |
| Michel Demare | CEO / chair | 1 | — | 303.0k GBP | 2026-09-14 | +4.5% | fewer than 5 completed |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.850 | 29.8 |
| Qualified-buy size | 25% | 1.000 | 25.0 |
| Role informativeness (inverted) | 20% | 0.000 | 0.0 |
| Recency | 10% | 0.102 | 1.0 |
| Buy/sell conviction | 10% | 1.000 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Since 2026-10-13: no longer on the bear side: price down over six months. All bull and bear lists, and what followed each line in the past →
Where the evidence comes from
Independent evidence does not object: the purchases themselves carry bull lines (several insiders together, senior executive buying); share price and trading, short sellers, company results were checked and none crosses a bear threshold. No data is held for: company actions.
- The insider purchases themselvesBullseveral insiders together, senior executive buying Bearvalue concentrated in one buyer, small purchases4 checked, under the threshold · 3 missing
- Share price and trading3 checked, under the threshold
- Short sellers1 checked, under the threshold
- Company results1 checked, under the threshold · 1 missing
- Company actions1 missing
Bull case · the buying is informative
- 3 insiders bought on the same day (2026-09-14). Several people reaching the same decision at the same time is hard to put down to one person's circumstances.Record: after 5,401 earlier disclosures like this, the median 60-session excess return was −3.3%, within 1 percentage point of all comparable disclosures (−3.3%).
- The buyers include the CEO or chair, who sees more of the business than most filers. This site's score gives little or no credit for that: in its backtests purchases by senior executives did no better than other insiders' purchases.Record: after 8,797 earlier disclosures like this, the median 60-session excess return was −3.1%, within 1 percentage point of all comparable disclosures (−3.2%).
Bear case · discount it
- Pascal Soriot accounts for 96% of the value bought. The other 2 buyers add names more than money.Record: after 3,396 earlier disclosures like this, the median 60-session excess return was −3.4%, within 1 percentage point of all comparable disclosures (−3.5%).
- Net purchases of €9.0M are <0.01% of the company's market value (€230.7bn): a visible sum, a small one against the business.
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- Only one reading of profitability is held (profit margin 17%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
- The next scheduled results are on 2026-10-30. They are the first hard test of either reading.
- European notifications have no field saying whether a purchase was pre-arranged; there is no counterpart to the US 10b5-1 box. None of the 5 purchase lines mentions a plan, but a bare “Förvärv” does not rule one out.
- The filings give the size of each trade, not what the buyer already held. Whether a purchase added 1% to a personal stake or doubled it is not known.
Checked and under the threshold: 9, 1 close to it
- BearThe share price changed −16% over six months (three months +0.83%, one month +4.6%) and stands 19% below its 52-week high. Counted for the bear side from a fall of 20%. close to the threshold
- Either3 insiders bought in the last 180 days and 2 in the 180 days before. Bull when the number at least doubles and rises by two; bear when at least two bought before and no more buy now.
- Bear0 of 3 buyers filed as a person closely associated with a manager. Counted for the bear side from half.
- BearNo insider sale is recorded in the same 180 days.
- EitherThe latest purchase is 33 days old. Bull up to 14 days, bear from 90.
- BearOver three months the share price changed +0.83% and the median of 271 Healthcare companies changed −6.3%: ahead by 7 points. Counted for the bear side from 20 points behind.
- BearThe register of Finansinspektionen shows no published net short position in this company. Positions under 0.5% are never published, so this does not show that nobody is short.
- BearProfit margin on the latest captured figures is 17%. Counted for the bear side when negative.
- BearAbout €423.8M of the stock changes hands on an average day. Counted for the bear side below €500k.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Signal history
65.8 / 100
Latest recorded score
↓ -4.3 ptssince the first recorded snapshot on 2026-09-23; 25 calendar days observed
- Recorded snapshots
- 21
- First snapshot
- 2026-09-23
There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Less than 30 days of comparable history is available, so factor movement is not yet decomposed.
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 70.1
- 68.0
- 67.1
- 66.2
- 65.8
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-09-23 | 70.1 |
| 2026-09-24 | 69.8 |
| 2026-09-25 | 69.4 |
| 2026-09-28 | 68.5 |
| 2026-09-29 | 68.3 |
| 2026-09-30 | 68.0 |
| 2026-10-01 | 67.8 |
| 2026-10-02 | 67.6 |
| 2026-10-03 | 67.6 |
| 2026-10-04 | 67.6 |
| 2026-10-05 | 67.1 |
| 2026-10-06 | 66.9 |
| 2026-10-07 | 66.8 |
| 2026-10-08 | 66.6 |
| 2026-10-09 | 66.5 |
| 2026-10-12 | 66.2 |
| 2026-10-13 | 66.1 |
| 2026-10-14 | 66.0 |
| 2026-10-15 | 65.9 |
| 2026-10-16 | 65.8 |
| 2026-10-18 | 65.8 |
Sector context
- Buying breadth
- 6.1% (48 / 792 issuers)
- Sector rank
- #11 / 12
- 7D breadth change
- -0.4 pp · vs 2026-10-12 (6d)
- 30D breadth change
- History building
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -0.2% | -0.1% | -1.0% |
| 20D | 3Small sample | 100.0% (3/3) | 66.7% (2/3) | +1.7% | +1.2% | -3.6% |
| 60D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -7.0% | -7.0% | -7.0% |
| 120D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -24.2% | -24.2% | -24.2% |
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | +3.7% | +3.7% | -3.5% |
| 20D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | +2.7% | +2.7% | -1.5% |
| 60D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +8.2% | +8.2% | +1.7% |
| 120D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +8.6% | +8.6% | +2.8% |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 27.2%
- Beta
- 0.20
- Avg daily volume
- £427.0M
VALUATION
- Market cap
- £194.7B
- P/E
- 25.1×
FUNDAMENTALS
- Profit margin
- 17.0%
- ROE
- 22.0%
- Industry
- Drug Manufacturers - General
Prices to 15 Oct 2026: OpenBB/yfinance. From OpenBB/yfinance, captured 15 Oct 2026: Market cap, P/E, Profit margin, ROE, Beta, Industry. It does not affect the insider score or rank.
Disclosed net short positions
The Finansinspektionen register, read 18 Oct 2026, publishes no net short position of 0.5% or more in this issuer. Positions below 0.5% are never published, so this is not evidence that nobody is short.
Short-position disclosures are external context; they do not affect the insider score, ranking, or filing eligibility.
Insiders' buying price vs the latest close
Insiders paid 121.03 GBP a share on average (2 purchase lines, 2 buyers, 2026-09-14 – 2026-09-14). The close on 2026-10-15 was 4.9% above that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored. 6 more purchase lines could not be compared with the share price and are left out.
Buying size vs market trading
0.00% · of estimated traded value in the same period
2026-09-18 – 2026-10-15 · 20 recorded trading sessions
- Disclosed qualifying purchases
- 0 GBP
- Estimated market traded value
- 7,153,157,854 GBP
Market-data coverage: 508 verified sessions · Latest session: 2026-10-15 · Ratio status: Available
Recent and largest purchase events / preceding 60-session ADTV
- Sep 14 · Aradhana Sarin · Ekonomichef/finanschef/finansdirektör— · —Some purchases lack a valid value; aggregate ratio withheld.
- Sep 14 · Michel Demare · Styrelseordförande303,033 GBP · —Quote currency is not verified.
- Sep 14 · Pascal Soriot · Verkställande direktör (VD)7,261,200 GBP · —Quote currency is not verified.
- Aug 17 · Aradhana Sarin · Ekonomichef/finanschef/finansdirektör— · —Some purchases lack a valid value; aggregate ratio withheld.
- May 14 · Pascal Soriot · Verkställande direktör (VD)— · —Some purchases lack a valid value; aggregate ratio withheld.
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Latest news
No news has been captured for this company.
Regulatory filings
The filing records held for this company carry no link to the original notice.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
8 qualifying purchase disclosure(s) · 8 transaction line(s)
Sep 14, 2026Förvärv
Pascal Soriot · Verkställande direktör (VD)
Aktie · 60000.0 shares × 121.02 GBP · —
Sep 14, 2026Förvärv
Aradhana Sarin · Ekonomichef/finanschef/finansdirektör
Aktie · 73.0 shares × 0.0 GBP · —
Sep 14, 2026Förvärv
Michel Demare · Styrelseordförande
Aktie · 2500.0 shares × 121.213296 GBP · —
Unfold all 5 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | 2026-08-19 | Aradhana Sarin | Ekonomichef/finanschef/finansdirektör | Förvärv | Aktie | 0.0 GBP | GBP | 11133.0 | — |
| 2026-05-14 | 2026-05-18 | Pascal Soriot | Verkställande direktör (VD) | Förvärv | Aktie | 0.0 GBP | GBP | 18359.0 | — |
| 2026-03-05 | 2026-03-06 | Pascal Soriot | Verkställande direktör (VD) | Förvärv | Aktie | 0.0 GBP | GBP | 101495.0 | — |
| 2026-03-04 | 2026-03-06 | Aradhana Sarin | Ekonomichef/finanschef/finansdirektör | Förvärv | Aktie | 0.0 GBP | GBP | 4863.0 | — |
| 2026-03-04 | 2026-03-06 | Pascal Soriot | Verkställande direktör (VD) | Förvärv | Aktie | 0.0 GBP | GBP | 14967.0 | — |
Showing 8 of 8 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 7 other transaction(s)
Mar 4, 2026Tilldelning
Aradhana Sarin · Ekonomichef/finanschef/finansdirektör
Aktie · 42393.0 shares × 152.42 GBP · —
Mar 4, 2026Tilldelning
Pascal Soriot · Verkställande direktör (VD)
Aktie · 103581.0 shares × 152.42 GBP · —
Dec 18, 2025Avyttring
Nazneen Rahman · Styrelseledamot
Aktie · 297.0 shares × 134.96 GBP · —
Unfold all 4 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-17 | 2025-12-18 | Philip Broadley | Styrelseledamot | Gåva mottagen | Aktie | 0.0 GBP | GBP | 5735.0 | — |
| 2025-12-17 | 2025-12-18 | Philip Broadley | Styrelseledamot | Gåva lämnad | Aktie | 0.0 GBP | GBP | 5735.0 | — |
| 2025-11-12 | 2025-11-14 | Aradhana Sarin | Ekonomichef/finanschef/finansdirektör | Avyttring | Depåbevis | 88.6345 USD | USD | 15000.0 | — |
| 2025-11-07 | 2025-11-10 | Pascal Soriot | Verkställande direktör (VD) | Gåva lämnad | Aktie | 0.0 GBP | GBP | 136537.0 | — |
Showing 7 of 7 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Snapshot & identity
- Snapshot date
- 2026-10-18
- Ticker
- AZN.L
- ISIN
- GB0009895292
- Sector
- Healthcare
- Industry
- Drug Manufacturers—General
Company logos by Parqet